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CASE PRESENTATION
The patient is an 18-month-old boy from Romania, whose
parents are healthy and non-consanguineous. In October
2005, periorbital and lower extremities edema were first
noted while the child was in general good conditions and
without any sign of acute infectious problem. For
generalized edema, he was admitted at a pediatric
nephrology unit where heavy proteinuria (410 g day1),
with serum high cholesterol levels (4500 mg per 100 ml)
and hypoalbuminemia (o1.5 g per 100 ml) were rapidly
discovered. The urine microscopic analysis showed
moderate microscopic hematuria, epithelial cells, and
granular casts. Serum creatinine was normal. Serology was
negative for hepatitis B, hepatitis C, EBV, HIV, and
parvovirus B19. Complement profile was normal and tests
for autoimmunity (ANA, nDNA, and ANCA) were negative.
No focal neurological defects were observed. He was
immediately treated with diuretics and infusions of
albumin and soon started prednisone 2.3 mg kg1 day1.
After the first 4 weeks of therapy, his edema increased and
he developed anasarca. ACE inhibitors (5 mg per 1.73 m2)
were added to the therapy, and a genetic approach
considering major inherited diseases was adopted that
excluded mutations relative to NPHS1 and NPHS2. Then, a
renal biopsy was performed.
As the clinical features did not improve, the patient
underwent a unilateral nephrectomy and started a
peritoneal dialysis program. Part of the clinical history of
this patient has been described in detail elsewhere,1 while
the findings on renal biopsy and nephrectomy that are
crucial for a correct differential diagnosis are described
together in the next paragraph.
KIDNEY BIOPSY AND NEPHRECTOMY FINDINGS
Sections from the needle biopsy (Figure 1) showed a
fragment of skeletal muscle as well as renal cortex with 19
glomeruli, some of which revealed collapsing features of
glomerular damage. Sections from the nephrectomy (Figure 1)
showed a more advanced disease with 25% globally sclerotic
glomeruli, 25% of the glomeruli having global collapse, and
50% with segmental collapse. No mesangial sclerosis was
identified. Marked podocyte hypertrophy and hyperplasia with
either a foamy appearance or large vacuoles, and protein
reabsorption droplets were present. In addition, PAS and silver-
positive small inclusion in perinuclear location, probably
representing accumulation of mitochondria, were seen in
podocytes and other cell types. Proximal tubules contained
numerous PAS-positive vacuoles as well as optically clear
vacuoles. Large microcysts, and patchy interstitial fibrosis and
tubular atrophy were noted, and were also more pronounced in
the nephrectomy specimen compared with the biopsy, indicat-
ing progression of the disease. Mild inflammation of lympho-
cytes, monocytes, and plasma cells accompanied the areas of
fibrosis. Arterioles and arteries were unremarkable.
Immunohistochemical analysis was performed with
selected antibodies and main results are reported in Figures
2 and 3 and Table 1. Glomeruli revealed segmentally reduced
synaptopodin expression and positive staining for Ki-67 in
the areas of pseudocrescents formation. Contrariwise,
synaptopodin expression was well preserved in the areas
where podocytes were markedly hypertrophic but not
hyperplastic. Podocin and b-dystroglycan expression were
also preserved. Podocytes were not dysregulated in their
phenotype as the expression of WT-1 was maintained and
PAX2 expression, normally regulated by WT-1, was absent in
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podocyte but positive in parietal cells nuclei. CK 17 staining
was very focally and segmentally weakly positive in parietal
cells, and podocytes with a perinuclear pattern. CK 7, 8,
and 19 were strongly positive, in few hyperplastic and
hypertrophic podocytes and in parietal cells (1% of
glomeruli). CK 20 was negative (not shown).
On ultrastructural analysis, the glomerular capillary walls






Figure 1 | Morphologic features of CoQ2 CG. (a) Renal biopsy: global collapse of the glomerular basement membranes is present and
accompanied by hypertrophy and hyperplasia of podocytes. PAS-positive granules are noted in podocyte cytoplasm, especially in perinuclear
location, suggesting the presence of mitochondria (PAS, original magnification  60). (b) Section from the nephrectomy specimen shows
severe tubulointerstitial damage, microcyst formation, and glomerular collapse (silver, original magnification  20). (c) Higher power shows
global wrinkling and folding of the glomerular basement membranes with occlusion of capillaries. Podocytes are markedly hypertrophic and
hyperplastic, and contain large intracytoplasmic vacuoles (silver, original magnification  60). (d) Fragment of skeletal muscle obtained with
the renal biopsy showing focal atrophic myocytes (asterisks) and accumulation of PAS-positive granules underneath the sarcolemma and in
perinuclear location (PAS, original magnification  40). (e) Electron micrograph of a fragment of a glomerulus. Note the collapsed capillary
walls and the hypertrophic overlying podocytes containing numerous organelles, most of which are mitochondria (arrows). Numerous
mitochondria are also noted in mesangial and endothelial cells. (f) High magnification of dysmorphic mitochondria in podocytes. Note the
truncated cristae and the central clear core.
Synaptopodin Podocin β-dystroglycan
Ki-67 WT-1 PAX2
Figure 2 | Podocyte phenotype in CoQ2 CG. Synaptopodin expression is preserved in most of podocytes, except for those cells that are part
of pseudocrescents. The arrow shows two detached podocytes part of the pseudocrescents still expressing synaptopodin (original
magnification  60). Podocin and b-dystroglycan staining are also preserved at the abluminal side of podocytes (original magnification  60).
b-dystroglycan is also positive in between the cells forming the pseudocrescents. Ki-67 expression is upregulated in podocyte nuclei in
pseudocrescents, indicating dedifferentiated phenotype (original magnification  60). Contrary from what was expected, WT-1 expression is
well preserved in podocyte nuclei of pseudocrescents, indicating that the dysregulation does not occurs (original magnification  60).
PAX2 is positive in parietal cells but not in podocytes (original magnification  60).
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focal loss of primary processes, extensive foot process
effacement, and contained numerous vacuoles. Many of
the intracytoplasmic vacuoles appeared to be dismorphic
mitochondria, from 0.78 to 1.2 mm in diameter, with
absent or truncated cristae. In addition, a central double
membrane ring was occasionally noted, but no classic
‘parking lot inclusions’ (paracrystalline intramitochondrial
inclusions) were identified. Abnormal mitochondria were
also in parietal, endothelial, and mesangial cell cytoplasm in
glomeruli and fibroblast, tubular cells, smooth muscle and
endothelial cells of the tubulointerstitial compartment. No
electron-dense deposits or tubuloreticular inclusions were
present.
The fragment of skeletal muscle revealed abnormal
myocytes with loss of the typical striate appearance and
formation of a reddish band at the border of the cells
resembling ragged red fibers. On occasion, myocytes
appeared filled with vacuolated PAS-positive granules, which
also were fuschinophilic on trichrome staining, in the
perinuclear areas and in the region underneath the
sarcolemma.
Pathologic diagnosis
Collapsing glomerulopathy (CG) associated with
mitochondrial abnormalities—consider inherited mito-
chondriopathy.
GENETIC STUDIES
After the results of the renal biopsy, additional studies on
mitochondria functionality and genetic analysis were per-
formed on the patient’s DNA. The results of the molecular
workup have been described in details elsewhere.1 Briefly,






Figure 3 | CKs expression in NFK, NAK, and CoQ2 CG. CK 7 is negative in S-shape body stage in NFK and mature podocyte in NAK.
CK 7 is positive in some of the cells forming pseudocrescents. CK 8 is positive in some podocytes at the capillary loop stage in NFK (arrow),
but it is negative in podocytes in NAK. Rare parietal cells are positive in NAK. Cells forming pseudocrescents are strongly positive for CK 8 in
CoQ2 CG, indicating dedifferentiation. Parietal cells are also focally positive in CoQ2 CG. CK 17 is negative in NFK and NAK, and only weakly
positive in podocytes in CoQ2 CG. CAM 5.2 is positive in some podocytes at the capillary loop stage in NFK (arrow), but it is negative in
podocytes in NAK. Rare parietal cells are positive in NAK. Cells forming pseudocrescents are strongly positive for CAM 5.2 in CoQ2 CG,
indicating dedifferentiation. CK 19 is positive in some podocytes at the capillary loop stage in NFK (arrow), but it is negative in podocytes in
NAK. Rare parietal cells are positive in NAK. Cells forming pseudocrescents are strongly positive for CK 19 in CoQ2 CG, indicating
dedifferentiation. Images of CK staining from NFK and NAK are at original magnification  40, and images of CoQ2 CG are at original
magnification  60.
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genes involved in Mendelian forms of mitochondrial
pathologies were analyzed. First, prenyltransferase-like
mitochondrial protein, the human ortholog of the murine
gene responsible for a spontaneous mouse model of CG was
negative. Instead, the child was found to carry a compound
heterozygous mutation in the gene encoding for CoQ2
(c.590G4A (p.Arg197His) and a c.683A4G (p.Asn228Ser),
which was associated with markedly decreased CoQ10 levels
and complex IIþ III activities in the renal cortex. The
c.590G4A was also heterozygous in the mother, whereas the
p.Asn228Ser mutation was also heterozygous in the father
and in the healthy brother. Other family members showed no
relevant renal symptoms.
CLINICAL CONCLUSIONS AND FOLLOW-UP
The final diagnosis was CoQ2-associated CG. At the last
follow-up, nearly 2 years after the initial presentation, the
patient is on chronic peritoneal dialysis and is growing well.
He is currently awaiting a renal transplantation and is treated
with oral ubiquinone supplementations. His neurological
examination has been checked periodically and has always
been found to remain normal.
DISCUSSION
Mitochondrial injury may be due to primary insults or may
be the result of secondary events; the former are known as
mitochondriopathies or mitochondrial cytopathies.
Mitochondriopathies are due to sporadic or spontaneous
mutations in the mitochondrial DNA (mtDNA) or nuclear
DNA (nDNA), in genes encoding structural or functional
mitochondrial proteins. They display extreme heterogeneity,
which is both genetic and clinical, and make unpredictable
the extent and manifestations of disease presentation.2 These
disorders have been considered as neuromuscular diseases,
but recently, involvement of other organs has been
described.3 The screening for mitochondrial disorders
includes the determination of lactate, pyruvate, ketone
bodies and their molar ratios in fasted and fed patients,
polarographic, and spectrometric studies to evaluate the
different enzymatic complexes of the respiratory chain,
histologic studies (generally muscle biopsies), and genetic
analysis.4
Renal disease may be the first sign of a mitochondrial
disorder,5 or it may appear simultaneously with neurological
and neuromuscular signs (Table 2). Fanconi’s syndrome is
particularly frequent in newborns, whereas tubule–interstitial
damage is more frequent in children and young adults, and
can be associated with focal segmental glomerulosclerosis
(FSGS).6 Hereditary FSGS has also been described in rare
cases associated with mitochondrial tRNALeu and tRNATyr
gene mutation.7–13 Two genetically transmitted forms of
nephrotic syndrome associated with mutations of a gene
of the CoQ cascade have lately been reported. The first form
of the disease is associated with mutations in the gene COQ2
Table 1 | Podocytes and parietal cell phenotype in normal fetal and adult kidney, and CG



















Synaptopodin  +      
Podocin  +  +    
b-dystroglycan + + + + + + + +
PAX2 +  +  + + + +
WT-1 + +  + +   
Ki-67 +  + + +   
CK 7   + (only in
pseudocres-
cents)
+ (very focal in
pseudocrescents)










 + (only in
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CK 17    (?) + (very focal in
pseudocrescents)



























 + (focally in
pseudocr-
escents)














CK 20        
CG, collapsing glomerulopathy.
Note: ‘diffuse’X50% of glomeruli; ‘segmental’=only few podocytes or parietal cells are positive; ‘very focal’=onlyo5% of the glomeruli have positive staining in podocytes or
parietal cells; ‘(?)’=is probably due to sampling error, since CK 17 and CAM 5.2 were only very rarely positive (o1%) in glomeruli from the patient’s nephrectomy.
In CoQ2 CG, synaptopodin expression is lost only in pseudocrescents; whereas, in other forms of CG, synaptopodin is generally not expressed in all podocytes.
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encoding the para-hydroxybenzoate-polyprenyl-transferase
enzyme of the CoQ10 synthesis pathway. Patients with
mutations in this gene present with morphologic features of
CG or classic FSGS, and it has been suggested that, due to
morphologic heterogeneity, the disease should be termed
COQ2 nephropathy.1 The other form was described in a child
who carried mutations of the PDSS2, gene encoding for
decaprenyl diphosphate synthase, which is the first enzyme of
the CoQ10 biosynthetic pathway.14 This patient presented
with Leigh’s syndrome, including severe postnatal hypotonia,
early-onset epileptic encephalopathy, and respiratory failure,
and developed nephrotic syndrome at 7 months of age.14
Brain magnetic resonance imaging (MRI) showed bilateral
symmetric areas of increased T2- and decreased T1-signal
intensity in the basal ganglia. mtDNA-associated Leigh
syndrome (subacute necrotizing encephalomyelopathy) and
NARP (neurogenic muscle weakness, ataxia, and retinitis
pigmentosa) are part of a continuum of progressive
neurodegenerative disorders observed in members of the
same family caused by abnormalities of mitochondrial energy
generation. In particular, Leigh syndrome is characterized by
an early onset of neurologic symptoms (3–12 months of age)
including hypotonia, spasticity, movement disorders, cere-
bellar ataxia, and peripheral neuropathy. Extraneurologic
manifestations may include hypertrophic cardiomyopathy.
Eleven mutations in several mitochondrial genes have been
associated with the disease (MTATP6, MTTL1, MTTK,
MTND1, MTND3, MTND4, MTND5, MTND6, MTCO3,
MTTW, and MTTV), and approximately 10–20% of indivi-
duals with Leigh syndrome have either the T8993G or
T8993C MTATP6 mutation. Interestingly, PDSS2 is the
human homolog of prenyltransferase-like mitochondrial
protein encoding a gene mapped on mouse chromosome 10,
and resulting in a spontaneous mouse model of CG.15,16 The
genetic defect is phenotypically reflected by the presence of
numerous dismorphic mitochondria in several cell types,
including podocytes. Mice develop exclusively renal symptoms
by 8 weeks of life, without any other organ being functionally
affected.16
Primary mitochondrial dysfunction and respiratory chain
deficiency were also described in two boys and a girl with
severe congenital nephrotic syndrome and normal nephrin
expression, but none of the patients had collapsing pattern of
glomerular injury.17
Secondary mitochondrial abnormalities may also result
from a few primary injuries at the level of the slit diaphragm,
suggesting a crucial role of these organelles for limiting severe
podocyte injury and fatal renal failure.18 Children with
congenital nephrotic syndrome of Finnish type, for example,
have mitochondria abnormalities, reflected by downregula-
tion of COX I mRNA to 25% of normal kidney values. In
addition, transcripts of other proteins encoded by mtDNA
are downregulated in kidneys with congenital nephrotic
syndrome of Finnish type, whereas mitochondria proteins
encoded in the nDNA are generally expressed at comparable
levels to normal kidney.18 Secondary mytochondrial dysfunc-
tion with reduction of the respiratory chain enzymatic
activity, oxygen consumption, and mtDNA copy number
have also been described in experimental FSGS induced by
puromycin.19
Mitochondriopathies and CG
Human CG can be idiopathic, genetically determined or
secondary to various etiologic factors.20 CG has been
described in three patients with action myoclonus–renal
failure syndrome.21 CG associated with dismorphic mito-
chondria and genetic defect in the gene encoding for CoQ2 is
a very rare disease, and only one case was found in the
pathology archives of three different institutions (NYU in
New York, UNC in Chapel Hill, and Bambino Gesu`
Children’s Hospital in Rome). CoQ2-associated CG signifi-
cantly differs from other mitochondriopathies with glomer-
ular involvement for the severe nephrotic syndrome at
presentation with very rapid progression into renal failure,
Table 2 | Mitochondriopathies associated with glomerular damage
Glomerular
morphology Mutations affecting nDNA Mutation affecting mtDNA Renal symptoms




Single deleted mtDNA in a
heteroplasmic state
4.9-kb deletion in mtDNA
tRNALeu (MELAS)
tRNATyr
Steroid-resistant subnephrotic proteinuria or







Not known Steroid-resistant severe nephrotic syndrome
and rapid renal failure
Nonsyndromic
COQ2 (CoQ2 NP)
CG, collapsing glomerulopathy; DMH, diffuse mesangial hypercellularity; mtDNA, mitochondrial DNA; nDNA, nuclear DNA; FSGS, focal segmental glomerulosclerosis; MELAS,
mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes; NP, nephropathy; PDSS2, decaprenyl diphosphate synthase.
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versus subnephrotic proteinuria and slower course of the
disease in patients with FSGS and tRNALeu gene mutation.7–9
Foot process effacement is not due to an intrinsic damage of
the slit diaphragm, as demonstrated by immunohistochemi-
stry and genetic analyses. Moreover, the morphologic
pattern of injury is significantly different from FSGS or
congenital nephrotic syndrome: the glomerular damage
resembles morphologically and (at least partially) pheno-
typically CG (with podocyte proliferation) rather than classic
FSGS (with podocyte depletion). However, differently from
HIV-associated or idiopathic forms of CG, where podocytes
are diffusely dedifferentiated and dysregulated,22 in CoQ2-
associated CG, the podocyte dedifferentiation is focal and
restricted to the areas of pseudocrescent formation. Similarly,
there is no dysregulation as there is preserved expression of
WT-1. Because PAX2 expression is maintained low under the
control of WT-1, staining for PAX2 is negative in CoQ2-
associated CG but PAX2 expression is upregulated in
dysregulated podocytes in HIV-CG. Podocin expression is
preserved where podocytes are markedly hyperplastic.
Synaptopodin is also preserved in some of the detached cells
forming pseudocrescents. The immunohistochemical analysis
with podocyte markers suggests that podocytes are the key
players in pseudocrescent formation, and indicates that there
is variability in podocyte phenotype between subcategories of
CG, which may also reflect pathogenetic mechanisms and
guide therapeutic approaches.
Whether functional defects associated with mitochondrial
abnormalities (such as neurological, and muscle problems or
functional defects of the proximal renal tubule) are wide-
spread in several organs or restricted to one cell type, it is
unpredictable in which cell type and to which degree a
functional damage will manifest. In cases where the mutation
is affecting mtDNA, heteroplasmy may explain this phenom-
enon, but this is not applicable to cases where the mutation is
affecting the nDNA. Cells most affected by mitochondrio-
pathies are those with little post-birth mitotic activity, such as
podocytes or neuronal cells. Threshold expression may also
affect the cell phenotype.23 Much has to be learned in the
field of mitochondrial defects and podocytes damage. It is
reasonable to think that, in the presence of mitochondrial
abnormalities in podocytes, cell death will occur and,
according to the cell depletion hypothesis, segmental sclerosis
may then develop.24 Different from expectation, in CoQ2-
associated CG, proliferation and glomerular collapse, rather
then podocyte death and glomerulosclerosis, were the
pathologic findings. The mechanism by which podocytes
react to mitochondria malfunctioning with proliferation
rather than cell death is not fully clear. It has been suggested
that ion channels in the inner membranes of mitochondria
have a potential role in redox regulation and have a central
role in the decision between life and death in ischemic
myocardial injury. Reduction of the cellular redox state may,
on one hand, induce programmed cell death, and, on the
other hand, activate transcription factor hypoxia-inducible
factor 1 with consequent increase expression of adaptive
enzymes, resulting in protection of the cells from death.25,26
The recent demonstration of hypoxia-inducible factor 1
potency to modulate podocyte phenotype and induction of
proliferation is in support of these observations.27–29 It is
possible that environmental factors may also be involved in
the manifestation and progression of the disease phenotype
through mechanisms involving the redox state of these
organelles. To support this hypothesis is the evidence that
germfree conditions markedly reduce the appearance of
mitochondrial phenotype in the kd/kd mouse.30
CONCLUSION
In conclusion, although CG associated with mutation in a
nuclear gene encoding mitochondrial proteins seems to be a
rare condition, evaluation of mitochondrial morphology is an
important screening in patients with unexplained proteinuria.
The described findings also stress the importance of accurate
clinical–pathologic correlation and call for complete genetic
analyses to avoid unnecessary interventions in patients.
DISCLOSURE
The authors state no conflict of interest.
REFERENCES
1. Diomedi-Camassei F, Di Giandomenico S, Santorelli FM et al. COQ2
nephropathy: a newly described inherited mitochondriopathy with
primary renal involvement. J Am Soc Nephrol 2007; 18: 2773–2780.
2. Finsterer J. Mitochondriopathies. Eur J Neurol 2004; 11: 163–186.
3. Finsterer J. Overview on visceral manifestations of mitochondrial
disorders. Neth J Med 2006; 64: 61–71.
4. Niaudet P. Mitochondrial disorders and the kidney. Arch Dis Child 1998;
78: 387–390.
5. Ueda Y, Ando A, Nagata T et al. A boy with mitochondrial disease:
asymptomatic proteinuria without neuromyopathy. Pediatr Nephrol 2004;
19: 107–110.
6. Mochizuki H, Joh K, Kawame H et al. Mitochondrial encephalomyopathies
preceded by de-Toni-Debre-Fanconi syndrome or focal segmental
glomerulosclerosis. Clin Nephrol 1996; 46: 347–352.
7. Gucer S, Talim B, Asan E et al. Focal segmental glomerulosclerosis
associated with mitochondrial cytopathy: report of two cases with special
emphasis on podocytes. Pediatr Dev Pathol 2005; 8: 710–717.
8. Cheong HI, Chae JH, Kim JS et al. Hereditary glomerulopathy associated with a
mitochondrial tRNA(Leu) gene mutation. Pediatr Nephrol 1999; 13: 477–480.
9. Dinour D, Mini S, Polak-Charcon S et al. Progressive nephropathy
associated with mitochondrial tRNA gene mutation. Clin Nephrol 2004;
62: 149–154.
10. Hirano M, Konishi K, Arata N et al. Renal complications in a patient with
A-to-G mutation of mitochondrial DNA at the 3243 position of leucine
tRNA. Intern Med 2002; 41: 113–118.
11. Hotta O, Inoue CN, Miyabayashi S et al. Clinical and pathologic features of
focal segmental glomerulosclerosis with mitochondrial tRNALeu(UUR)
gene mutation. Kidney Int 2001; 59: 1236–1243.
12. Kurogouchi F, Oguchi T, Mawatari E et al. A case of mitochondrial
cytopathy with a typical point mutation for MELAS, presenting with
severe focal-segmental glomerulosclerosis as main clinical manifestation.
Am J Nephrol 1998; 18: 551–556.
13. Scaglia F, Vogel H, Hawkins EP et al. Novel homoplasmic mutation in the
mitochondrial tRNATyr gene associated with atypical mitochondrial
cytopathy presenting with focal segmental glomerulosclerosis. Am J Med
Genet A 2003; 123: 172–178.
14. Lopez LC, Schuelke M, Quinzii CM et al. Leigh syndrome with
nephropathy and CoQ10 deficiency due to decaprenyl diphosphate
synthase subunit 2 (PDSS2) mutations. Am J Hum Genet 2006; 79:
1125–1129.
15. Barisoni L, Madaio MP, Eraso M et al. The kd/kd mouse is a
model of collapsing glomerulopathy. J Am Soc Nephrol 2005; 16:
2847–2851.
242 Kidney International (2008) 74, 237–243
t h e r e n a l c o n s u l t L Barisoni et al.: COQ2-associated collapsing glomerulopathy
16. Peng M, Jarett L, Meade R et al. Mutant prenyltransferase-like
mitochondrial protein (PLMP) and mitochondrial abnormalities in kd/kd
mice. Kidney Int 2004; 66: 20–28.
17. Goldenberg A, Ngoc LH, Thouret MC et al. Respiratory chain deficiency
presenting as congenital nephrotic syndrome. Pediatr Nephrol 2005; 20:
465–469.
18. Holthofer H, Kretzler M, Haltia A et al. Altered gene expression and functions
of mitochondria in human nephrotic syndrome. FASEB J 1999; 13: 523–532.
19. Hagiwara M, Yamagata K, Capaldi RA et al. Mitochondrial dysfunction in
focal segmental glomerulosclerosis of puromycin aminonucleoside
nephrosis. Kidney Int 2006; 69: 1146–1152.
20. Albaqumi M, Soos TJ, Barisoni L et al. Collapsing glomerulopathy. J Am
Soc Nephrol 2006; 17: 2854–2863.
21. Badhwar A, Berkovic SF, Dowling JP et al. Action myoclonus–renal failure
syndrome: characterization of a unique cerebro-renal disorder. Brain
2004; 127: 2173–2182.
22. Barisoni L, Kopp JB. Modulation of podocyte phenotype in collapsing
glomerulopathies. Microsc Res Tech 2002; 57: 254–262.
23. Hauser P, Oberbauer R. Tubular apoptosis in the pathophysiology of renal
disease. Wien Klin Wochenschr 2002; 114: 671–677.
24. Wiggins JE, Goyal M, Sanden SK et al. Podocyte hypertrophy, ‘adaptation,’
and ‘decompensation’ associated with glomerular enlargement and
glomerulosclerosis in the aging rat: prevention by calorie restriction. J Am
Soc Nephrol 2005; 16: 2953–2966.
25. O’Rourke B, Cortassa S, Aon MA. Mitochondrial ion channels:
gatekeepers of life and death. Physiology (Bethesda) 2005; 20:
303–315.
26. O’Rourke B. Mitochondrial ion channels. Annu Rev Physiol 2007; 69:
19–49.
27. Ding M, Cui S, Li C et al. Loss of the tumor suppressor Vhlh leads to
upregulation of Cxcr4 and rapidly progressive glomerulonephritis in
mice. Nat Med 2006; 12: 1081–1087.
28. Hellwig-Burgel T, Stiehl DP, Wagner AE et al. Review: hypoxia-inducible
factor-1 (HIF-1): a novel transcription factor in immune reactions.
J Interferon Cytokine Res 2005; 25: 297–310.
29. Pouyssegur J, Mechta-Grigoriou F. Redox regulation of the hypoxia-
inducible factor. Biol Chem 2006; 387: 1337–1346.
30. Hallman TM, Peng M, Meade R et al. The mitochondrial and kidney
disease phenotypes of kd/kd mice under germfree conditions.
J Autoimmun 2006; 26: 1–6.
Kidney International (2008) 74, 237–243 243
L Barisoni et al.: COQ2-associated collapsing glomerulopathy t h e r e n a l c o n s u l t
